Abstract
Primary Fallopian Tube Carcinomas are rare and share many clinical and histo- pathological features with primary peritoneal and high grade serous carcinomas of ovary. The three have a considerable overlap in pathogenesis and clinical course leading to the view of them being a single entity. Due to the same reason, International Federation of Obstetrics and Gynecology (FIGO) 2014, in the latest staging have staged them collectively with the clause of designating the primary wherever possible. Presenting symptoms of fallopian tube carcinoma are vague. The diagnosis is generally made in retrospect in women operated for adnexal mass. Imaging studies have not shown to be of much help in pre-operative diagnosis. Management strategies are same for all three regardless of their ovarian, tubal, or peritoneal derivation. Due to rarity, no randomized trials are available exclusively for FTC and most treatment strategies have been extrapolated from epithelial ovarian cancers.
In recent times, there has been a rapidly increasing body of evidence supporting the tubal origin for all high grade serous carcinomas of ovary. This has led to growing interest in the strategy of prophylactic salpingectomy rather than salpingooophorectomy as a preventive measure for ovarian carcinomas.
Keywords: Fallopian tube, serous carcinoma, salpingo-oophorectomy, TIC.
Reviews on Recent Clinical Trials
Title:Management of Fallopian Tube Cancer
Volume: 10 Issue: 4
Author(s): Shweta Rai and Amita Maheshwari
Affiliation:
Keywords: Fallopian tube, serous carcinoma, salpingo-oophorectomy, TIC.
Abstract: Primary Fallopian Tube Carcinomas are rare and share many clinical and histo- pathological features with primary peritoneal and high grade serous carcinomas of ovary. The three have a considerable overlap in pathogenesis and clinical course leading to the view of them being a single entity. Due to the same reason, International Federation of Obstetrics and Gynecology (FIGO) 2014, in the latest staging have staged them collectively with the clause of designating the primary wherever possible. Presenting symptoms of fallopian tube carcinoma are vague. The diagnosis is generally made in retrospect in women operated for adnexal mass. Imaging studies have not shown to be of much help in pre-operative diagnosis. Management strategies are same for all three regardless of their ovarian, tubal, or peritoneal derivation. Due to rarity, no randomized trials are available exclusively for FTC and most treatment strategies have been extrapolated from epithelial ovarian cancers.
In recent times, there has been a rapidly increasing body of evidence supporting the tubal origin for all high grade serous carcinomas of ovary. This has led to growing interest in the strategy of prophylactic salpingectomy rather than salpingooophorectomy as a preventive measure for ovarian carcinomas.
Export Options
About this article
Cite this article as:
Rai Shweta and Maheshwari Amita, Management of Fallopian Tube Cancer, Reviews on Recent Clinical Trials 2015; 10(4) . https://dx.doi.org/10.2174/1574887110666150923112556
DOI https://dx.doi.org/10.2174/1574887110666150923112556 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Targeted Drug Delivery Systems and Their Therapeutic Applications in Cancer and Immune Pathological Conditions
Infectious Disorders - Drug Targets Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Screening for Infectious Diseases During Pregnancy: Which Test and Which Situation
Current Women`s Health Reviews Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Psychological Sequelae of Ovarian Cancer Screening and Genetic Testing for Ovarian Cancer Susceptibility
Current Women`s Health Reviews Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets The Ovary Feels Fine when Paracrine and Autocrine Networks Cooperate with Gonadotropins in the Regulation of Folliculogenesis
Current Pharmaceutical Design Proteomic Classification of Breast Cancer
Current Drug Targets Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study
Current Protein & Peptide Science The Role of Aromatase Enzyme in Hormone Related Diseases and Plant- Based Aromatase Inhibitors as Therapeutic Regimens
Current Topics in Medicinal Chemistry Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets WNT4 Signaling in Female Gonadal Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry Role of Farletuzumab in Epithelial Ovarian Carcinoma
Current Pharmaceutical Design Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Current Gene Therapy